The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells

Journal of Cellular Biochemistry

Volumn 116, Issue 10, 2015, Pages 2210-2226

  Choe, Moran ^a,d   Brusgard, Jessica L ^a   Chumsri, Saranya ^a   Bhandary, Lekhana ^a   Zhao, Xianfeng Frank ^a,b   Lu, Song ^a   Goloubeva, Olga G ^a   Polster, Brian M ^a   Fiskum, Gary M ^a   Girnun, Geoffrey D ^a,c   Kim, Myoung Sook ^a   Passaniti, Antonino ^a,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

B REAST C ANCER; G LYCOLYSIS; M ETABOLISM; M ITOCHONDRIAL R ESPIRATION; T RANSCRIPTION

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; LACTATE DEHYDROGENASE; MESSENGER RNA; PROTEIN; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE A1; PYRUVATE DEHYDROGENASE KINASE; SIRTUIN 6; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; RUNX2 PROTEIN, HUMAN; SIRT6 PROTEIN, HUMAN; SIRTUIN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BREAST CANCER CELL LINE; CANCER GROWTH; EDITORIAL; ENZYME REPRESSION; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL PROLIFERATION; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; GLYCOLYSIS; HUMANS; MCF-7 CELLS; NEOPLASM PROTEINS; OXIDATIVE PHOSPHORYLATION; SIRTUINS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84939182991     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25171     Document Type: Article

References (55)

1. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC,. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64: 4506-4513.
2. Berman HK, Gauthier ML, Tlsty TD,. 2010. Premalignant breast neoplasia: A paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev Res (Phila) 3: 579-587.
3. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW,. 2008. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 25: 629-642.
4. Cairns RA, Harris IS, Mak TW,. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
5. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS,. 2009. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
6. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B,. 2011. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 13: R127.
7. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B,. 2012. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: In vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 18: 901-911.
8. Clerc P, Polster BM,. 2012. Investigation of mitochondrial dysfunction by sequential microplate-based respiration measurements from intact and permeabilized neurons. PLoS ONE 7: e34465.
9. D'Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, Passaniti A,. 2009. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J Biol Chem 284: 17947-17955.
10. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M,. 2009. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 45: 2239-2248.
11. Deepak V, Zhang Z, Meng L, Zeng X, Liu W,. 2011. Reduced activity and cytoplasmic localization of Runx2 is observed in C3h10t1/2 cells overexpressing Tbx3. Cell Biochem Funct 29: 348-350.
12. Dimri G, Band H, Band V,. 2005. Mammary epithelial cell transformation: Insights from cell culture and mouse models. Breast Cancer Res 7: 171-179.
13. Dranka BP, Hill BG, Darley-Usmar VM,. 2010. Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 48: 905-914.
14. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A,. 2012. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 38: 698-707.
15. Ferrari N, McDonald L, Morris JS, Cameron ER, Blyth K,. 2013. RUNX2 in mammary gland development and breast cancer. J Cell Physiol 228: 1137-1142.
16. Fukumura D, Jain RK,. 2007. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 74: 72-84.
17. Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, Roca H, Franceschi RT,. 2009. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 284: 32533-32543.
18. Guttilla IK, Adams BD, White BA,. 2012a. ERalpha, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 23: 73-82.
19. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA,. 2012b. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132: 75-85.
20. Herman MA, Kahn BB,. 2006. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 116: 1767-1775.
21. Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S,. 2008. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 25: 549-557.
22. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Hunter C, Jenkinson A, Jones D, Kosmidou V, Lugg R, Menzies A, Mironenko T, Parker A, Perry J, Raine K, Richardson D, Shepherd R, Small A, Smith R, Solomon H, Stephens P, Teague J, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Reinhold W, Weinstein JN, Stratton MR, Futreal PA, Wooster R,. 2006. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
23. Kanfi Y, Shalman R, Peshti V, Pilosof SN, Gozlan YM, Pearson KJ, Lerrer B, Moazed D, Marine JC, de Cabo R, Cohen HY,. 2008. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett 582: 543-548.
24. Kim J, Villadsen R, Sorlie T, Fogh L, Gronlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H, Edwards PA, Borresen-Dale AL, Ronnov-Jessen L, Bissell MJ, Petersen OW,. 2012. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci USA 109: 6124-6129.
25. Kim S, Koga T, Isobe M, Kern BE, Yokochi T, Chin YE, Karsenty G, Taniguchi T, Takayanagi H,. 2003. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev 17: 1979-1991.
26. Kwon TG, Zhao X, Yang Q, Li Y, Ge C, Zhao G, Franceschi RT,. 2011. Physical and functional interactions between Runx2 and HIF-1alpha induce vascular endothelial growth factor gene expression. J Cell Biochem 112: 3582-3593.
27. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S,. 2006. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520.
28. Lee NK, Karsenty G,. 2008. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 19: 161-166.
29. Mahlknecht U, Ho AD, Voelter-Mahlknecht S,. 2006. Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene. Int J Oncol 28: 447-456.
30. Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, Seluanov A, Gorbunova V,. 2011. SIRT6 promotes DNA repair under stress by activating PARP1. Science 332: 1443-1446.
31. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA,. 2011. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011: 282745.
32. Massague J,. 2008. TGFbeta in Cancer. Cell 134: 215-230.
33. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, Alt FW,. 2006. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315-329.
34. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW,. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
35. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H,. 2010. Runx2 in human breast carcinoma: Its potential roles in cancer progression. Cancer Sci 101: 2670-2675.
36. Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL, Stein GS,. 2013. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol 228: 1784-1792.
37. Pierce AD, Anglin IE, Vitolo MI, Mochin MT, Underwood KF, Goldblum SE, Kommineni S, Passaniti A,. 2012. Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype. J Cell Biochem 113: 218-292.
38. Pockwinse SM, Rajgopal A, Young DW, Mujeeb KA, Nickerson J, Javed A, Redick S, Lian JB, van Wijnen AJ, Stein JL, Stein GS, Doxsey SJ,. 2006. Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2. J Cell Physiol 206: 354-362.
39. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM,. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
40. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS,. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25: 589-600.
41. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A,. 2006. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 281: 7118-7128.
42. Qiao M, Shapiro P, Kumar R, Passaniti A,. 2004. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a PI3K/ERK-dependent and Akt-independent signaling pathway. J Biol Chem 279: 42709-42718.
43. Schroeder TM, Jensen ED, Westendorf JJ,. 2005. Runx2: A master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 75: 213-225.
44. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, Macdonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R,. 2012. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151: 1185-1199.
45. Sellick CA, Reece RJ,. 2005. Eukaryotic transcription factors as direct nutrient sensors. Trends Biochem Sci 30: 405-412.
46. Semenza GL,. 2009. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16.
47. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE,. 2010. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660.
48. Underwood KF, D'Souza DR, Mochin MT, Pierce A, Kommineni S, Choe M, Bennett J, Gnatt A, Habtemariam B, Mackerell AD, Jr., Passaniti A,. 2012. Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by Vitamin D3 (cholecalciferol) prohormone activity. J Bone Min Res 27: 913-925.
49. Vander Heiden MG, Cantley LC, Thompson CB,. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
50. Vitolo MI, Anglin IE, Mahoney WM, Jr., Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A,. 2007. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 6: 856-863.
51. Wu D, Gambhir SS,. 2003. Positron emission tomography in diagnosis and management of invasive breast cancer: Current status and future perspectives. Clin Breast Cancer 4 (Suppl 1): S55-S63.
52. Yun SJ, Yoon HY, Bae SC, Lee OJ, Choi YH, Moon SK, Kim IY, Kim WJ,. 2012. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer Prostatic Dis 15: 369-373.
53. Zhang J, Khvorostov I, Hong JS, Oktay Y, Vergnes L, Nuebel E, Wahjudi PN, Setoguchi K, Wang G, Do A, Jung HJ, McCaffery JM, Kurland IJ, Reue K, Lee WN, Koehler CM, Teitell MA,. 2011. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. Embo J 30: 4860-4873.
54. Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D,. 2003. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 278: 27939-27944.
55. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R,. 2010. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280-293.